Bayer plans to shift focus away from women’s health drug research

Bayer, one particular of the world’s premier pharmaceutical providers, announced on Friday that it will be shifting its target away from women’s health.

The corporation strategies to put a lot more exploration endeavours into scarce ailments, cardiovascular disorder, neurology, oncology and immunology.

“When it arrives to investigation and the subsequent medical phases, we will no more time have an express target on women’s wellbeing,” the head of Bayer’s prescription drugs unit, Stefan Oelrich, instructed Reuters. 

BE Very well: SPRING-Clear YOUR Medication Cabinet TO Clear away EXPIRED Prescription drugs

Even so, the corporation — which makes the common client prescription drugs Aleve, Midol, MiraLAX, Alka-Seltzer and Claritin — will continue growth of elinzanetant, a non-hormonal treatment supposed to treat menopausal symptoms.

Bayer, a single of the world’s premier pharmaceutical organizations, has declared that it will be shifting its focus away from women’s overall health. (iStock / iStock)

Bayer’s immunology investigate could even now end result in some women’s wellness prescription drugs, but the company’s focused endeavours on therapeutics experienced unsuccessful to satisfy anticipations, Oelrich explained to Reuters. 

The company will go on advancement of elinzanetant, a non-hormonal treatment meant to treat menopausal symptoms. (iStock / iStock)

The corporation will as a substitute goal to grow its existence in cell and gene therapy.

BREAST Cancer AND MAMMOGRAMS: Anything YOU Want TO KNOW ABOUT THE Ailment, SCREENING AND Far more

Bayer also can make the Yasmin manufacturer of birth-command pills and the Mirena intrauterine device.

Bayer options to grow its existence in cell and gene treatment. (iStock / iStock)

The announcement comes just prior to a leadership adjust at the organization. 

On April 1, Bill Anderson will step into the CEO function, having over as Werner Baumann retires.  

Click on Right here TO Signal UP FOR OUR Overall health E-newsletter

In other women’s wellness medicine information, the Swiss pharma corporation Novartis has described optimistic trial info for its breast-most cancers treatment method Kisqali.

GET FOX Organization ON THE GO BY CLICKING In this article

In a firm assertion, Novartis claimed the drug exhibited good topline benefits from an interim evaluation of NATALEE, a Section III demo analyzing Kisqali, in a wide inhabitants of clients with early breast most cancers.

Joe Toppe of FOX Business, as well as Reuters, contributed reporting to this write-up.